文章：

一线滤泡性淋巴瘤中期PET/CT评估影响的探索性研究

Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma

原文发布日期：21 March 2025

DOI: 10.3390/cancers17071065

类型: Article

开放获取: 是

英文摘要：

Background/Objectives: This study aimed to determine whether interim PET/CT (iPET) scans could identify follicular lymphoma (FL) patients at high risk of relapse following first-line therapy.Methods: A total of 117 FL patients who underwent iPET scans were included, with responses interpreted using the Deauville score (DS). Progression-free survival (PFS) was evaluated over a median follow-up of 34 months.Results: Overall, 34% of patients were classified as iPET (+), with significantly worse estimated 5-year PFS compared to iPET (−) patients (34% vs. 76%, hazard ratio 4.3,p< 0.001). Multivariate analysis confirmed iPET (+) as an independent predictor of PFS.Conclusions: Interim PET results are significant predictors of PFS in FL first-line therapy and could inform response-adapted treatment strategies.

摘要翻译： 

背景/目的：本研究旨在探讨中期PET/CT扫描能否识别一线治疗后具有高复发风险的滤泡性淋巴瘤患者。方法：共纳入117例接受中期PET/CT扫描的滤泡性淋巴瘤患者，采用Deauville评分系统评估治疗反应。在中位随访34个月期间评估无进展生存期。结果：总体而言，34%的患者被判定为中期PET阳性，其预估5年无进展生存率显著低于中期PET阴性患者（34%对比76%，风险比4.3，p<0.001）。多变量分析证实中期PET阳性是无进展生存期的独立预测因子。结论：中期PET扫描结果是滤泡性淋巴瘤一线治疗中无进展生存期的重要预测指标，可为制定个体化治疗策略提供依据。

原文链接：

Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma